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Abstract We have determined the nucleotide sequence of the
clone pAL2 obtained from Porphyromonas gingivalis 381 in the
previous study [Ansai et al. (1995) Microbiology 141, 2047^
2052]. The DNA sequence analysis of this fragment revealed one
complete ORF and one incomplete ORF. The ORF encoded a
protein (PgPepO) of 690 amino acids with a calculated
molecular weight of 78 796. The deduced amino acid sequence
exhibited a significant homology with human endothelin-con-
verting enzyme (ECE)-1. Recombinant PgPepO was purified to
homogeneity and characterized. The purified enzyme was
strongly inhibited by phosphoramidon, and converted big
endothelin-1 to endothelin-1. Furthermore, the purified PgPepO
strongly cross-reacted with a monoclonal antibody against rat
ECE-1. These results indicate that PgPepO has striking
similarity to mammalian ECE in structure and function.
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1. Introduction
Adult periodontitis is a chronic in£ammatory disease in-
duced by a microbial infection that is the major cause of tooth
loss in the adult population [1]. Although a variety of bacte-
rial species are associated with the initiation and progression
of periodontitis, accumulated evidence suggests that Porphyr-
omonas gingivalis, a Gram-negative anaerobe, is an important
pathogen in severe manifestation of the disease [1,2]. P. gin-
givalis has been shown to express a variety of factors which
may play signi¢cant roles in pathogenicity, including adhesins,
proteases, endotoxins, and cytotoxins [3]. These proteases are
considered to be involved directly in tissue invasion and de-
struction by bacteria and in evasion and modulation of host
immune defences, though the primary function of proteases is
to provide peptides for growth [4].
Recently, some reports have described the association be-
tween periodontal diseases and coronary artery diseases [5].
Also, several studies suggest that some bacteria and viruses
contribute to the development of atherosclerosis and coronary
artery diseases [6,7]. Endothelin-1 (ET-1) has been identi¢ed
as the most potent vasoconstrictor peptide produced by endo-
thelial cells [8]. ET-1 is generated by a unique proteolytic
cleavage of big endothelin-1 (bigET-1), which is catalyzed
by endothelin-converting enzyme (ECE)-1 [9]. Elevation of
ET-1 levels has been implicated in the pathogenesis of several
diseases, including atherosclerosis [10] and heart failure [11].
While studying an approximately 3.8 kb DNA fragment
(pAL2) which we have previously cloned [12], we found that
it contained a DNA fragment encoding a novel protease.
Here, we report the identi¢cation and characterization of
the protease homologous to human ECE-1, designated PgPe-
pO, from P. gingivalis 381.
2. Materials and methods
2.1. Materials
The endopeptidase 24.11 (NEP) substrate [Met]-enkephalin
(YGGFM), bradykinin (RPPGFSPFR), substance P (RPKPQQF-
FGLM), and succinyl-RPFHLLVY-7-amino-4-methylcoumarin were
obtained from Sigma (St. Louis, MO, USA). A precoated 0.25 cm
thick silica gel 60 plate was purchased from Merck (Darmstadt, Ger-
many). The peptides human bigET-1, bigET-2 and bigET-3 were ob-
tained from Peptide Institute Inc. (Osaka, Japan).
2.2. Bacterial strains and plasmids
P. gingivalis 381, P. gingivalis ATCC 33277, P. gingivalis W83,
Actinobacillus actinomycetemcomitans Y4, and Prevotella intermedia
ATCC 25611 were kindly provided by K. Ishihara, Tokyo Dental
College, Japan and grown anaerobically as described previously
[12]. Escherichia coli JM109 and BL21(DE3)pLysS (Novagen) were
used in subcloning and expression experiments. All E. coli strains
were grown on LB agar plates or LB broth (Difco Laboratories,
Detroit, MI, USA) in the presence of appropriate antibiotics (ampi-
cillin, 50 Wg/ml; chloramphenicol, 34 Wg/ml).
2.3. DNA sequence analysis
Plasmid pAL2 [12] was used as a template in sequencing reactions
and sequenced by the dideoxy method of Sanger et al. [13] with a dye
terminator sequencing kit (Applied Biosystems) together with a syn-
thetic oligonucleotide primer. The sequence was determined with an
Applied Biosystems model 373S automated DNA sequencer. The cod-
ing region was sequenced and con¢rmed on both strands by using
overlapping fragments. The nucleotide sequences were analyzed with
computer software package ‘DNA strider v. 1.2’ [14]. Amino acid
homology and comparisons were done with GENETYX-Mac soft-
ware (Software Development Co., Ltd., Japan) and BLAST network
services of DDBJ.
2.4. Southern blot analysis
Genomic DNAs from P. gingivalis 381, P. gingivalis ATCC 33277,
P. gingivalis W83, A. actinomycetemcomitans Y4, and P. intermedia
ATCC 25611 were isolated as previously described [12]. Southern blot
analysis was performed as previously described [12] using digoxigenin-
labelled probes according to the instructions of the supplier (Boeh-
ringer Mannheim).
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2.5. Enzyme assay
Endopeptidase activity was measured using succinyl-RPFHLLVY-
7-amino-4-methylcoumarin as a substrate. Reaction mixtures con-
tained 20 mM Tris-HCl bu¡er, 25 WM substrate and enzyme in a ¢nal
volume of 0.1 ml. Enzyme assays were performed as described [15].
The optimal pH was determined using 20 mM acetate bu¡er (pH
3.5^6.5) and 20 mM Tris-HCl bu¡er (pH 6.5^9.5).
The measurements of endopeptidase activity were also carried out
using thin-layer chromatography (TLC) as follows: the reaction mix-
ture containing 1.25 mM [Met]-enkephalin in 20 mM Tris-HCl bu¡er
(pH 7.0) was incubated with an appropriate amount of enzyme for
10 min at 37‡C. The reaction was terminated on ice, and the mixture
(5 Wl) was then spotted onto a precoated 0.25 cm thick silica gel
60 plate, and TLC was performed as described [16]. Essentially similar
methods were carried out on the other substrates such as bradykinin
and substance P.
2.6. Expression and puri¢cation of PgPepO gene in E. coli
The open reading frame (ORF) in pAL2 was subcloned in the T7-
based bacterial expression plasmid pET3a (Novagen) as follows. The
gene was ampli¢ed by the following primers (corresponding to the
5P- and 3P-ends of the gene, respectively): 5P-TATGCTTTACATAT-
GAACAAGACAATCAAG-3P and 5P-AGAGCGAGGATCCTTAC-
CAAACGACTACAC-3P (the NdeI and BamHI sites are underlined).
The PCR product was restricted with NdeI and BamHI and cloned
into the same sites of pET3a. The resulting clone, pET3a-PgPepO,
was con¢rmed by DNA sequencing, and introduced into E. coli
BL21(DE3)pLysS. Growth of the transformant, induction with iso-
propyl-1-thio-L-D-galactopyranoside (IPTG), and lysis with lysosome
were carried out essentially as described previously [17]. The crude
enzyme extract from sonicate of induced cells was applied to a column
of Resource Q equilibrated with 25 mM Tris-HCl bu¡er (pH 7.5)
connected to a FPLC system (Amersham Pharmacia Biotech, Swe-
den). The column was washed with the equilibration bu¡er, and
then developed with a linear gradient of NaCl (0^1 M) in the bu¡er.
The active fraction was subjected to HPLC using TSK-gel
G3000SWXL (Tosoh, Japan) pre-equilibrated with 25 mM Tris-HCl
bu¡er (pH 7.5), which was also used for determination of the molec-
ular mass of PgPepO. For molecular weight standards, the MW-
Marker kit was used (Oriental Yeast, Japan). The puri¢ed enzyme
was frozen and stored at 380‡C.
2.7. SDS-PAGE and immunoblotting
SDS-PAGE was performed with a 12% gel, according to the meth-
od of Laemmli [18], and the gel was stained with Coomassie blue
R250. Proteins were subjected to 12% polyacrylamide gels containing
SDS followed by transfer to a PVDF membrane for immunoblot
(Western) analysis using monoclonal antibody AEC27-121 (1:2000)
[19] and the ECL method (Amersham).
2.8. E¡ect of various chemicals on enzyme activity
The puri¢ed enzymes were preincubated for 30 min at 37‡C with
phosphoramidon, thiorphan, EDTA, ZnCl2, pCMB, DEP, PAO, o-
phenanthroline, phenylglyoxal, antipain or leupeptin in 50 mM Tris-
HCl bu¡er (pH 7.0), 150 mM NaCl, 0.1 WM ZnCl2 and 0.1% BSA
(bu¡er A). The reaction mixture was incubated for 15 min at 37‡C
with 0.1 WM bigET-1 and terminated by the addition of 100 Wl of
5 mM EDTA. The reaction products were analyzed using EIA kit
(Cayman Chemical Co., Ann Arbor, MI, USA).
2.9. Determination of Km and Vmax for bigET-1, bigET-2,
and bigET-3
The enzymatic conversions of bigETs to ETs were carried out in
100 Wl bu¡er A including 0.1 WM bigET-1, bigET-2 or bigET-3. The
reaction mixtures were incubated for 15 min at 37‡C and the reactions
were terminated by adding 100 Wl of 5 mM EDTA. The amount of the
generated ET-1, ET-2 or ET-3 was measured by the EIA kit as de-
scribed above. For the determination of Km and Vmax, bigET-1, big-
ET-2 and bigET-3 were used at concentrations in the range 0.05^
5 WM. Reaction condition was maintained such that hydrolysis was
linear with respect to time and protein concentration.
2.10. Nucleotide sequence accession number
The GenBank accession number for the nucleotide sequence of
PgPepO reported in this paper is AB010440.
3. Results
3.1. Nucleotide and amino acid sequence analysis
We have determined the nucleotide sequence of a 3804 bp
DNA fragment (pAL2) of P. gingivalis 381. The total se-
quence contained one complete ORF and one incomplete
ORF. The nucleotide sequence and deduced amino acid se-
quence of the ORF are shown in Fig. 1. The ORF contained
2070 bp encoding a putative polypeptide of 690 amino acids
with a calculated molecular mass of 78 796 Da and an esti-
mated pI of 5.33. A potential ribosome binding site was not
identi¢ed (data not shown).
The ¢rst 25 amino acid residues appeared to have the pu-
tative signal sequence as de¢ned by the criteria of von Heijne
[20] (Fig. 1). The deduced amino acid sequence corresponding
to the ORF was compared to all proteins in the Swiss-Prot
database with the GENETYX-Mac program (Software Devel-
opment). A signi¢cant degree of sequence homology was
found between the ORF and ECE-1 of human (31.1% identi-
cal residues) [21], NEP of human (29.9% identical residues)
[22], endopeptidase (PepO) from Lactococcus lactis (formerly
Streptococcus lactis) (L. lactis PepO) (28.3% identical residues)
[23] and endopeptidase from Mycobacterium leprae (38.0%
identical residues) (unpublished data, accession number
Z95398), which all belong to the NEP family. Therefore, the
ORF was named PgPepO. The zinc binding motif (HEXXH)
among zinc metalloproteases including the NEP family [24]
was conserved from position 526 to 530 of PgPepO (Fig. 1).
The PgPepO also had the two consensus sequences of the zinc
binding domains found among the ECE and NEP family from
position 523 to 532, and from position 585 to 594, and con-
tained the glutamic acid (Glu-587) at position 62 downstream
of the N-terminal side (i.e. His-526) of the motif HEXXH
(Fig. 1). The alignment of the amino acid sequences of Pg-
PepO and the human ECE-1 are shown in Fig. 2. The putative
active sites in human ECE-1 were conserved in PgPepO (Arg-
78, Asn-485, Ala-486, Val-523, Glu-527, Glu-587, Asp-591,
His-649 and Arg-655) (Fig. 2, box). On the other hand, all
10 cysteine residues (Fig. 2, arrow) conserved in the ECE and
NEP family [24] were replaced by other amino acid residues.
3.2. Puri¢cation of recombinant PgPepO and immunoblotting
The puri¢cation of recombinant PgPepO is summarized in
Table 1. The enzyme was puri¢ed 41-fold with a ¢nal speci¢c
activity of 24.6 U/mg, and the overall yield of the activity was
0.7%. Upon induction of E. coli BL21(DE3)pLysS containing
pET3a-PgPepO with IPTG, a polypeptide of Mr V78 kDa
was produced (Fig. 3A), which is in good agreement with the
calculated molecular mass of the predicted amino acid se-
quence (78 796 Da). The molecular mass of PgPepO was esti-
mated by gel ¢ltration to be about 78 kDa. These results
suggested that PgPepO was a monomer of V78 kDa poly-
peptide.
The 78 kDa protein corresponding to PgPepO cross-reacted
e¡ectively against the anti-rat ECE monoclonal antibody,
AEC27-121, as shown in Fig. 3B.
3.3. Characterization of PgPepO
The optimal pH for PgPepO was determined in vitro by
using succinyl-RPFHLLVY-7-amino-4-methylcoumarin as a
substrate. The optimal pH value for the activity was in a
narrow neutral range between 6.8 and 7.0, similar to ECE-1
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(pH 6.6^6.8) [25]. To characterize PgPepO further, the e¡ect
of various chemicals on the enzymatic activity was investi-
gated by using bigET-1 as a substrate, which was a speci¢c
substrate of ECE in vivo, as shown in Table 2. In this experi-
ment, we did not use the assay system using succinyl-
RPFHLLVY-7-amino-4-methylcoumarin as substrate since
some chemicals were found to inhibit the activity of amino-
peptidase M (data not shown). In the bigET-1 conversion
Fig. 1. Nucleotide and deduced amino acid sequence of PgPepO. The putative signal sequence is doubly underlined. The consensus sequences
including zinc binding motif conserved in NEP family are underlined.
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assay, the enzyme was strongly inhibited by the NEP inhib-
itor, phosphoramidon, as well as by o-phenanthroline, EDTA,
pCMB and PAO, and moderately inhibited by DEP, phenyl-
glyoxal, leupeptin and antipain. However, the enzyme was
resistant to another potent NEP inhibitor, thiorphan, as is
the case for ECE-1. Also, the enzyme activity was activated
by 10 mM Zn2.
Kinetic parameters of PgPepO for bigET-1, bigET-2, and
bigET-3 are shown in Table 3. The Km and Vmax values for
bigET-1 of PgPepO were 12.78 þ 3.24 nM and 3.33 þ 0.32
Wmol/minWmg, respectively, which indicated that bigET-1 was
converted most e⁄ciently, compared with bigET-2 and big-
ET-3.
3.4. Distribution of genes homologous to the PgpepO gene
As shown in Fig. 4, speci¢c signals for the PgPepO gene
were found in P. gingivalis strains including 381, ATCC 33277
and W83, but not detected in other periodontopathogenic
bacteria such as P. intermedia ATCC 25611 and A. actino-
mycetemcomitans Y4 strains.
4. Discussion
In the present study, we have identi¢ed and characterized a
novel endopeptidase gene, PgPepO gene, from P. gingivalis
381. PgPepO had signi¢cant homology to the NEP family
including human ECE-1. ECE-1, like mammalian NEP, is a
class II integral membrane protein with a short N-terminal
cytoplasmic tail, a transmembrane domain that represents
the uncleaved signal peptide, and a large putative extracellular
domain [24]. In contrast, PgPepO had a putative signal se-
Fig. 2. Alignment of amino acid sequences of PgPepO and human
ECE-1. The respective amino acid numbers starting from the N-ter-
minus are listed at the left margin. Asterisks and dots indicate iden-
tical amino acids and conservative amino acid substitutions, respec-
tively. The putative active site amino acids are boxed. Arrows show
cysteine residues conserved in the ECE and NEP family, which are
replaced with other amino acid residues in PgPepO.
Table 1
Puri¢cation of recombinant PgPepO
Fraction Total protein (mg) Total activity (U) Speci¢c activity (U/mg) Yield (%) Puri¢cation (fold)
Crude extract 80.3 49.2 0.6 100 1
Resource Q 2.3 48.3 21.0 2.8 35
TSK-gel G3000SWXL 0.6 14.8 24.6 0.7 41
One unit corresponds to the cleavage of 1 Wmol of succinyl-RPFHLLVY-7-amino-4-methylcoumarin per minute.
Fig. 3. SDS-PAGE and immunoblotting of PgPepO. A: Samples
from each puri¢cation step were resolved by SDS-PAGE in a 12%
gel and then stained with Coomassie blue R250. B: Samples for im-
munoblots were subjected to SDS-PAGE on a 12% gel, transferred
to a PVDF membrane and analyzed using monoclonal antibody
AEC27-121. The immunoreactive bands were visualized with the
ECL detection kit. Lane 1, the crude enzyme extract; lane 2, the en-
zyme preparation eluted from Resource Q; lane 3, the puri¢ed en-
zyme. The positions and molecular weights of standard proteins are
indicated in the left lane. The position and molecular weight of
PgPepO is indicated by the arrow in the right lane.
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quence in the N-terminal region, but it did not appear to
include any membrane-spanning domains. This indicated
that PgPepO may be secreted across the cytoplasmic mem-
brane by using the signal peptide. This ¢nding di¡ers from
L. lactisPepO, which is one of the prokaryotic endopeptidases
reported to date. In L. lactis PepO, the possible membrane-
spanning domains and typical signal sequence were not found.
In practice, L. lactis PepO was shown to be localized on the
inner side of the cell membrane [23].
PgPepO had the consensus sequences including zinc binding
sites (His-526, His-530, and Glu-587) and all the conserved
active sites in the NEP family [24], although Arg-747 of hu-
man NEP was replaced by Glu-751 in human ECE-1 and Val-
687 in PgPepO. These ¢ndings support well the results that
the arginine modi¢er, phenylglyoxal, and the histidine modi-
¢er, DEP, inhibited the enzyme activity (Table 2). Further-
more, interestingly, all 10 cysteine residues conserved in ECE
and NEP family were not conserved in PgPepO. However,
considering that PgPepO was inhibited by pCMB, PAO, leu-
peptin and antipain, which are known cysteine protease inhib-
itors, ¢ve cysteine residues in PgPepO might have important
roles in enzyme activity. On the other hand, it has been re-
ported that rat ECE-1 exists as a disul¢de-linked dimer, and
Cys-412 is responsible for the dimerization of rat ECE-1 [26].
In PgPepO, the amino acid residue corresponding to the Cys-
412 was replaced by Met-354. This observation would be rea-
sonable for the ¢nding that PgPepO is a monomer. Mutation-
al analysis is needed to clarify the exact roles of these amino
acid residues.
In our study, puri¢ed PgPepO was able to convert bigET-2
and bigET-3, although the enzyme preferred bigET-1 to big-
ET-2 or bigET-3, as does ECE-1. The Km values of PgPepO
for bigET-1, bigET-2 and bigET-3 was lower than ECE-1
(Km = 200, 460 and 270 nM, respectively) [25]. Therefore, it
was suggested that PgPepO might be able to convert bigET-1,
bigET-2 and bigET-3 to ET-1, ET-2 and ET-3 more e⁄ciently
than ECE-1. Furthermore, the puri¢ed enzyme also cleaved
[Met]-enkephalin as well as bradykinin and substance P (our
unpublished data), and succinyl-RPFHLLVY-7-amino-4-
methylcoumarin, which are known substrates of NEP [15].
In general, it has been considered that NEP has a much
broader substrate speci¢city compared with ECE-1. However,
recently ECE-1 has been shown to hydrolyze bradykinin e⁄-
ciently [27] and this study has been extended in [28] to show
that ECE-1 can also hydrolyze some other NEP substrates
such as substance P, neurotensin and insulin B chain but
[Leu]-enkephalin was hydrolyzed extremely poorly. These re-
sults suggest that PgPepO exhibits a similar substrate speci¢c-
ity to ECE-1 and NEP although further detailed kinetic stud-
ies will be required to compare the speci¢city of PgPepO with
its mammalian homologues more quantitatively. The sensitiv-
ity of PgPepO to phosphoramidon but not thiorphan also
emphasizes the greater similarity with ECE-1 than with NEP.
Thus, PgPepO has a striking similarity with human ECE-1
in structure and function. ET-1 acts as a potent mitogen on
various kinds of cells, including vascular smooth muscle cells
[29,30]. The mitogenic action is synergistic with the e¡ects of
other mitogens such as epidermal growth factor [31]. Most
Table 2
E¡ect of various chemicals on enzyme activity of PgPepO
Chemical (conc.) Activity (%)
None 100
Phosphoramidon (10 WM) 25
Thiorphan (10 WM) 93
EDTA (10 mM) 4
o-Phenanthroline (10 mM) 3
pCMB (10 mM) 3
PAO (10 mM) 22
DEP (10 mM) 58
Phenylglyoxal (10 mM) 41
Leupeptin (10 mM) 30
Antipain (10 mM) 65
ZnCl2 (10 mM) 173
The indicated amounts of inhibitor were preincubated for 30 min at
37‡C in bu¡er A with the puri¢ed enzyme (PgPepO) before the ad-
dition of 0.1 WM bigET-1. The reaction mixture was incubated for
15 min at 37‡C, stopped by adding 100 Wl of 5 mM EDTA and
tested for ET-1 concentration in EIA. Control activity (100%) was
determined in the absence of inhibitors. Data are the means of three
independent experiments.
Table 3
Kinetic parameters of PgPepO for bigET-1, bigET-2 and bigET-3
Substrate Km (nM) Vmax (Wmol/minWmg) Km/Vmax (minWmg/ml)
Big endothelin-1 (human, 1^38) 12.78 þ 3.24 3.33 þ 0.32 0.0037 þ 0.0005
Big endothelin-2 (human, 1^37) 38.43 þ 7.55 2.89 þ 0.23 0.0131 þ 0.0015
Big endothelin-3 (human, 1^41 amide) 49.00 þ 13.75 1.39 þ 0.02 0.0348 þ 0.0092
Results from three independent sets of experiments are shown as mean þ S.D. BigET-1, bigET-2 and bigET-3 were used at concentrations in
the range 0.05^5 WM. The amount of generated ET-1, ET-2 or ET-3 was measured by EIA.
Fig. 4. Southern blot hybridization of chromosomal DNA from
periodontopathogenic bacteria with the PgpepO gene. Lanes: 1,
P. gingivalis 381; 2, P. gingivalis ATCC 33277; 3, P. gingivalis
W83; 4, A. actinomycetemcomitans Y4; 5, P. intermedia ATCC
25611; 6, PgPepO gene probe; 1^5, EcoRI digests. The numbers on
the left are size markers.
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recently, common bacteria and viruses, such as Helicobacter
pylori, Chlamydia pneumoniae and cytomegalovirus, have been
reported to contribute to the development of atherosclerosis,
perhaps by triggering in£ammation [6,7]. Furthermore, several
studies have shown that periodontopathogenic bacteria may
have important roles in atherosclerosis [5]. P. gingivalis was
found to invade aortic and heart endothelial cells in vitro [32].
Also, it is reported that ET-1 production increases in vascular
smooth muscle, gastric epithelium and gastric smooth muscle
cells with H. pylori [33]. In the present study, Southern blot
analysis revealed that genes homologous to the PgPepO gene
were distributed in only P. gingivalis strains such as 381,
ATCC 25611 and W83 among periodontopathogenic bacteria.
Therefore, it is of interest whether P. gingivalis in£uences the
expression of ET-1 in endothelial cells and other cells. Addi-
tional studies are needed to investigate the exact nature and
function of PgPepO to the host.
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